Brief: Bellerophon Therapeutics Receives IND Clearance From China NMPA To Conduct Phase 3 Clinical Trial In China For INOpulse® In Fibrotic Interstitial Lung Disease
09/02/2023 19:09
Feb 9 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS RECEIVES IND CLEARANCE FROM CHINA
NMPA
TO CONDUCT PHASE 3 CLINICAL TRIAL IN CHINA FOR INOPULSE® IN
FIBROTIC INTERSTITIAL LUNG DISEASE
* BELLEROPHON THERAPEUTICS RECEIVES IND CLEARANCE FROM CHINA
NMPA
TO CONDUCT PHASE 3 CLINICAL TRIAL IN CHINA FOR INOPULSE® IN
FIBROTIC INTERSTITIAL LUNG DISEASE
Source text for Eikon: ID:nGNX3nNHwR
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen